The Role of S100 Calcium-binding Protein A1 and Some Biochemical markers in Patients with Ovarian Cancer

Abstract

Patients with epithelial ovarian cancer (EOC) typically receive a late-stage diagnosis since there are insufficient early diagnostic markers. The biomarker that is most commonly used is ovarian cancer antigen 125 (CA125). In order to increase sensitivity and specificity, particularly in cases of early illness, complementing markers are therefore required. The current study concentrated on the diagnosis of ovarian cancer patients using specific biochemical markers found in blood serum. Serum albumin, calcium, and phosphorus were among these markers that were thought to increase sensitivity and specificity, especially in early stages of the disease and facilitate effective early identification . Serum calcium-binding protein S100 A1 (S100A1) enhanced the growth and migration of ovarian cancer cells. When ovarian cancer patients are evaluated, serum levels of fibroblast growth factor 23 (FGF23) are recommended as a helpful indicator of advanced disease. Consequently, treatment for patients with ovarian cancer is aided by the early identification and diagnosis of metastases.